Prostate Cancer

A New England Journal of Medicine editorial by Dan L. Longo, MD, called the ability of Provenge to prolong the survival in prostate cancer patients without having any measurable effect on the tumor “surprising” and “hard to understand.”

Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. The extent of benefit and harm with widespread PSA screening is under continuous debate.

This article defines the biochemical recurrence of prostate cancer, distinguish SRT from ART, outline the evidence for SRT, and makes recommendations with regard to radiotherapy volume and dose.

Despite the common use of postoperative radiotherapy (RT) in patients managed initially with radical prostatectomy (RP), a number of questions remain. Raldow and colleagues build their arguments around three randomized trials that indicated a significant benefit of immediate adjuvant radiotherapy in patients with high-risk features.

In their article, Raldow et al provide an excellent summary of the issues surrounding the use of salvage radiotherapy for a post-prostatectomy recurrence. For practicing clinicians, the pressing issue is how to appropriately select patients for treatment with salvage radiotherapy.

Cancer survival notwithstanding, patients must still be encouraged to maintain a healthy lifestyle to help avoid progression.

The European Commission (EC) has granted marketing authorization for the RANK ligand inhibitor denosumab (Prolia) for treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. The European approval of Prolia marks its first approval worldwide. Amgen, the manufacturer of Prolia, announced the EC authorization on May 28, 2010.

Once PSA kinetics were thought to be a good way to predict which patients with early prostate cancer were at risk of progression. Now they're not. Even those who had the most hope for these biomarkers have evidence of their unreliability for this purpose.

Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist.

Cabazitaxel, an investigational taxane, significantly extended survival among prostate cancer patients whose disease had progressed despite hormone therapy.

The technique provides a new and continuously evolving tool in oncologic imaging for lesion detection, characterization, and therapy assessment.

ONCOLOGY board member Judd Moul, MD, told the CancerNetwork blog that there will be several controversial pro-con debates featured at this year’s Society of Urologic Oncology (SUO) meeting, May 29th in San Francisco. Dr. Moul will moderate a pro-con debate about the effectiveness of PSA screening during a session titled, Prostate Cancer I – Screening: Lessons from the PLCO and ESRPC Randomized Trials. Stand by for exclusive interviews and podcasts…

Almost 3 years after a controversial FDA denial, Provenge was approved, making it the first autologous cellular immunotherapy for prostate cancer. One pressing question about Provenge is how much its maker, the biotech company, Dendreon, would charge for its newly approved drug.

A new study supports previous findings that finasteride prevents prostate cancer. However, like much research in prostate cancer, the study leaves us with as many questions as answers.

Mismanaged therapy at one institution has dealt a blow to the field, but practitioners explain why the technique remains worthwhile.

One of the largest clinical trials classifies which patients will benefit most from androgen deprivation therapy paired with radiotherapy.

Most men who have had radical prostatectomy can look forward to at least 15 years free from prostate cancer. But which patients are likely to see their PSA levels double within nine months, and therefore have high risk of recurrence? Oncologists are calling for new ways to predic, and researchers are on the case.

Prostate cancer patients administered high doses of proton-beam therapy appear to have a markedly reduced risk of disease recurrence when compared with other low-risk patients treated with conventional radiation therapy, according to two recent studies.

In order for a new treatment modality to be considered efficacious, it needs to be evaluated by acceptable criteria and demonstrate an improvement on the natural course of the disease.

Over 40 million men and women in the United States have osteoporosis and low bone mineral density (BMD), placing them at risk for adverse skeletal events such as fractures and their sequelae. There are over 12 million cancer survivors in this country. Of these, 22% were diagnosed with breast cancer and 17% with prostate cancer.[1,2] Because cancer therapies can adversely influence bone health, these survivors are at particular risk for skeletal complications. Cancer therapies associated with bone loss include hormone deprivation therapies such as aromatase inhibitors, ablative surgical procedures that induce hypogonadal states, and premature menopause induced by chemotherapy.[3,4]

The first major study to address the cardiovascular adverse effects of endocrine therapy for prostate cancer could change attitudes toward treatment options because testosterone deprivation may have more impact on the patient’s life than it does on the androgen receptor.

Findings of a study by researchers in Italy suggest C-11 choline PET/CT could diagnose prostate cancer recurrence sooner than transrectal ultrasound, CT, MRI, or bone scintigraphy in patients who have undergone radical prostatectomy.

Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.

Dr. Otis W. Brawley took a courageous stand late last week, one he has taken many times before, but which had until then gone all but unnoticed. Responding to a Journal of the American Medical Association article detailing the scientific and medical limitations of breast and prostate screening, the chief medical officer of the American Cancer Society acknowledged that “in the case of some screening for some cancers, modern medicine has overpromised.”

The comparison of brachytherapy and surgery may be done on several levels. This review focuses the comparison on toxicity, the “soft” endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the “hard” endpoint of prostate cancer–specific mortality.